Endocrine Abstracts

Objectives: Radical prostatectomy is an effective therapy for men with clinically localized prostate cancer. A significant number of men develop erectile dysfunction after radical prostatectomy (PPED) due to intraoperatory cavernous nerve injury causing hypoxia and fibrosis of corpus cavernosus. We established an experimental model of bilateral cavernous neurotomy (BCN) in the rat in order to investigate whether sildenafil treatment in PPED patients could prevent penile tissue...

The metabolic syndrome (MetS) is a clustering of metabolic and cardiovascular risk factors, having in insulin resistance the key element. In males, MetS is also associated to hypogonadism. We recently found that high fat diet (HFD)-induced MetS rabbits also developed hypogonadotropic hypogonadism, showing a reduced immunopositivity for gonadotropin relasing hormone (GnRH) in the hypothalamus. In this study, we investigated the pathogenetic link between Mets components and the ...

The molecular mechanisms underlying the reawakening of hypothalamic GnRH neurons at puberty remain to be elucidated. Recently, the G protein-coupled receptor 54 (GPR54) and its endogenous ligand kisspeptin, encoded by the KISS1 gene, have been involved. In fact, GPR54 mutations cause idiopathic hypogonadotropic hypogonadism in human and mice. We used the previously characterized primary culture of human fetal olfactory GnRH-secreting neurons, FNC-B4, to study in vitro t...

The contractile RhoA/Rho-kinase (Rock) signalling pathway is up-regulated in penile tissue in animal models of experimental diabetes and has been proposed to contribute to diabetes-related erectile dysfunction (ED). In previous studies we demonstrated that testosterone (T) restores diabetes-induced ED by influencing the NO/cGMP/PDE5 pathway.AimTo investigate the effect of T on the RhoA/Rock signalling in course of diabetes.MethodsWe used two distinct animal models of chemical ...

Benign prostate hyperplasia (BPH) is the most common disease in the aging male, often comorbid with erectile dysfunction (ED). PDE5 inhibitors (PDE5i, sildenafil, tadalafil and vardenafil) decrease lower urinary tract symptoms (LUTS) in patients with ED and BPH. We studied PDE5 expression and activity in the human bladder and PDE5i effects both in vitro (human and rat) and in vivo (rat). PDE5 is highly expressed in rat and human bladder and immunolocalized in vas...